Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Semaglutide reduces cardiovascular events and body weight in T2D

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 12, 2026

Key finding

Semaglutide reduced major adverse cardiovascular events versus placebo.

This study evaluated the effects of semaglutide on cardiovascular events and body weight in adults with type 2 diabetes, finding significant reductions in several cardiovascular outcomes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

High Risk

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of semaglutide on cardiovascular events and body weight in adults with type 2 diabetes, finding significant reductions in several cardiovascular outcomes.

Clinical relevance

The findings are clinically significant as they suggest that semaglutide not only aids in weight management but also plays a crucial role in reducing serious cardiovascular risks in adults with type 2 diabetes. This could lead to improved long-term health outcomes and reduced healthcare costs associated with diabetes-related complications.

Keep in mind

The analysis was post hoc, which may introduce bias. Results may not be generalizable to all populations. The sample size for specific outcomes may limit robustness.

Published in

Journal Reference

Publication details and source links for this paper.

Stephen CB, Nicolas B, Søren TH, et al. Semaglutide Reduces Cardiovascular Events and Body Weight in Adults with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy. 2024;16(1):15-28. doi:10.1007/s13300-024-01659-7

View DOIView on PubMedView on PMC

Main Effects

Semaglutide reduced composite cardiovascular events by 25% (p=0.01).

Semaglutide decreased cardiovascular death by 20% (p=0.02).

Semaglutide led to a 15% reduction in nonfatal myocardial infarction (p=0.03).

Body weight decreased by 1.5% with semaglutide compared to placebo (p=0.01).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Body weight, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 3 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Body weight

Evidence topic

Cardiovascular Risk

Primary intervention

Semaglutide

Primary outcomes

  • Body weight
  • Cardiovascular death
  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular RiskHbA1c ReductionWeight LossGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

Body weightCardiovascular deathComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

4

Related topics

6

Evidence pairs

989

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 6 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and HbA1c

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and Body Weight

Save evidence

Evidence relationship

GLP-1 Receptor Agonists and Cardiovascular Outcomes

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Semaglutide → Body weight

Semaglutide → Body weight

Evidence Intelligence™
EvidenceScore™
85
Strong
ImpactScore™
72
Positive
ConsistencyScore™
88
consistent
Supporting studies: Based on 9 studies
Add to Evidence Tracker

Cardiovascular death

Semaglutide → Cardiovascular death

Semaglutide → Cardiovascular death

Evidence Intelligence™
EvidenceScore™
77
Strong
ImpactScore™
33
Slightly Negative
ConsistencyScore™
67
generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence Tracker

HbA1c

Semaglutide → HbA1c

Semaglutide → HbA1c

Evidence Intelligence™
EvidenceScore™
86
Strong
ImpactScore™
88
Very Positive
ConsistencyScore™
83
consistent
Supporting studies: Based on 12 studies
Add to Evidence Tracker

Incidence of myocardial infarction

Semaglutide → Incidence of myocardial infarction

Semaglutide → Incidence of myocardial infarction

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Nonfatal stroke

Semaglutide → Nonfatal stroke

Semaglutide → Nonfatal stroke

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 4 studies
ImpactScore™
38
Slightly Negative
ConsistencyScore™
35
mixed
Supporting studies: Based on 4 studies
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Semaglutide reduced major cardiovascular events by 25%.
  • Cardiovascular death decreased by 20% with semaglutide.
  • Body weight reduction of 1.5% was observed in the treatment group.
who this applies

Who this applies to

  • Adults aged 18 and older with type 2 diabetes.
  • Individuals at risk for cardiovascular events.
keep in mind

Keep in Mind

  • The study's post hoc nature may affect the reliability of findings.
  • Results may not apply to younger populations or those with different diabetes types.
  • Further studies are needed to confirm long-term effects and safety.
between the lines

Between the Lines

  • The analysis was post hoc, which may introduce bias.
  • Results may not be generalizable to all populations.
  • The sample size for specific outcomes may limit robustness.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists lower HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appear to lower HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 85.6 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.

33 supporting studies
View Full Evidence

Do GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.

33 supporting studies
View Full Evidence

Do GLP-1 Receptor Agonists improve cardiovascular outcomes?

Strong Evidence

GLP-1 Receptor Agonists may improve cardiovascular outcomes.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 1 study

  2. 2

    Nonfatal stroke

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak negative | ConsistencyScore™ Mixed | 1 study

  3. 3

    Cardiovascular death

    EvidenceScore™ Strong | EvidenceScore™ 77.1 | weak negative | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.

13 supporting studies
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence HubHbA1c Reduction Evidence HubWeight Loss Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and HbA1cAll studies on Semaglutide and Body weightAll studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Semaglutide and Nonfatal stroke

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.